Year: 2021

NEW YORK, Nov. 11, 2021 (GLOBE NEWSWIRE) — Tilray, Inc. (“Tilray”) (NASDAQ: TLRY; TSX: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, announced that the Company will participate in two Jefferies investor conferences.On Tuesday, November 16, 2021, the Company will participate in the Jefferies Virtual West Coast Consumer Conference. The fireside chat will begin at 2:00 PM ET. On Wednesday, November 17, 2021, the Company will participate in the Jefferies London Healthcare Conference. The fireside chat will begin at 11:20 AM ET.Please refer to the Investors section of the Company’s website at www.Tilray.com under “Events and Presentations” for webcast information. About Tilray Tilray, Inc. is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada,...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES BOCA RATON, Fla., Nov. 11, 2021 (GLOBE NEWSWIRE) — Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, announced it has filed a preliminary short form base shelf prospectus with the securities commissions in each of the provinces and territories of Canada (the “Shelf Prospectus”). The Shelf Prospectus, when made final and effective, will allow the Company to offer up to C$500 million of subordinate voting shares, subscription receipts, debt securities, convertible securities, warrants, and units (collectively, the “Securities”), or any combination thereof, from time to time during the 25-month period that the Shelf Prospectus is effective. The final short...

JENA, Germany, Nov. 11, 2021 (GLOBE NEWSWIRE) — InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, will present a corporate overview at the H.C. Wainwright 7th Annual Israel Conference. The session will take place virtually on Monday, November 15th at 8:00 am EST/2:00 pm CET and can be accessed via a live webcast on the InflaRx website in the Investors section under Events & Presentations. A replay will be available on the Company’s website following the live event. About InflaRx N.V.:InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class,...

AMGAS Enters into Service Agreement with US Noble Gas, LLC to Provide Exploration, Development, Production and Marketing Services Relative to AMGAS’s Potential Helium and other Noble Gas Reserves on its Recent Acquisition of 11,000 Leasehold Acres in Central Kansas Uplift Formation Lenexa, KS, Nov. 11, 2021 (GLOBE NEWSWIRE) — American Noble Gas, Inc. (OTC-QB: IFNY) (“AMGAS” or the “Company”). An independent oil, gas, and noble gas exploration and development company announced today it has entered into formed a new advisory board containing four world-class noble gas industry experts. The advisory board will provide unique guidance and experience to the Company as it evaluates its reserve potential of noble gases, specifically including helium, relative to its recently acquired 11,000-acre oil & gas properties in the Otis/Albert...

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), is a patient-focused, innovative, commercial-stage, global biopharmaceutical company. The company announced today that the first patient with primary immune thrombocytopenia (ITP) was treated with efgartigimod in Greater China (mainland China, Hong Kong, Macau, and Taiwan) as part of the global registrational ADVANCE-SC Phase 3 study. The ADVANCE-SC study is a randomized, double-blind, placebo-controlled, multi-center Phase 3 trial evaluating the efficacy and safety of subcutaneous (SC) efgartigimod in approximately 156 adult patients with primary ITP. In a prior Phase 2 study1, patients treated with efgartigimod exhibited clinically meaningful improvement in platelet counts across doses and types of ITP...

Positions Algoma for Long-Term Growth as a Leading North American Producer of Green Steel Dual furnaces to provide more liquid steel to match downstream finishing capacity.Transformation is expected to reduce carbon emissions by approximately 70%, positioning Algoma for long-term growth in the increasing market for green steel. SAULT STE. MARIE, Ontario, Nov. 11, 2021 (GLOBE NEWSWIRE) — Algoma Steel Group Inc. (NASDAQ: ASTL; TSX: ASTL) (“Algoma” or the “Company”), a leading Canadian producer of hot and cold rolled steel sheet and plate products, today announced that its Board of Directors has authorized the Company to construct two new state-of-the-art electric-arc-furnaces (EAF) to replace its existing blast furnace and basic oxygen steelmaking operations. The transformation is expected to reduce Algoma’s carbon emissions by approximately...

Figure 1Rayon d’Or and Vauquelin PropertiesFigure 2Rayon d’Or Drill MapFigure 3Regional Exploration MapTORONTO, Nov. 11, 2021 (GLOBE NEWSWIRE) — Petrolympic Ltd. (the ” Company “, TSXV: PCQ – OTC:PCQRF) is pleased to provide an update on its exploration projects and the potential of the Rayon d’Or and Vauquelin gold properties. Petrolympic is currently developing an exploration program to delineate the extensions of auriferous zones included in the Rayon d’Or and Vauquelin deformation corridor. In particular, the Company is undertaking an airborne magnetic survey followed by a ground Induced Polarization (IP) survey that will help to locate mineralized zones. Detailed mapping of the targeted areas and stripping as needed will follow these surveys, along with a...

CARSON CITY, NV, Nov. 11, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), is pleased to announce that in advance of its entry into the multi-billion dollar California cannabis industry and the development of its Tissue Culture Centre, the company has engaged its research and development corporate partner to commence developing tissue culture protocol for each of the top Cannabis Strains sold and grown in California. This cannabis market is estimated to be over $6 Billion annually.  The cannabis strains targeted for protocol development (scientific process for plant reproduction where each strain has its own protocol) are some of the top strains currently being grown in California by cultivators.  California market is very unique with well established, highly experienced breeders for...

BOSTON, Nov. 11, 2021 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in the following virtual investor conferences:The 2021 Jefferies London Virtual Healthcare Conference. The presentation will be available on-demand beginning at 3:00 a.m. ET/8:00 a.m. GMT on Thursday, November 18, 2021. The Piper Sandler 33rd Annual Virtual Healthcare Conference. The fireside chat will be available on-demand beginning at 10:00 a.m. ET on Monday, November 22, 2021.A replay of the pre-recorded presentations can be accessed from the Investor & News section of Inozyme’s website...

WARMINSTER, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different modes of action to provide a cure for people with chronic hepatitis B virus (HBV) infection and to treat coronaviruses (including COVID-19), today announced that Tram Tran, M.D. has been appointed to the Arbutus Board of Directors effective immediately. Dr. Tran is a renowned liver and viral specialist with over 20 years of academic and industry experience as a physician scientist. “We are excited to welcome Dr. Tran to the Arbutus Board,” said William Collier, President and Chief Executive Officer of Arbutus. “Her extensive medical and scientific expertise in the field of...